UWELL BioPharma

UWELL BioPharma, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotheraputics designed to harness the power of a patient’s own immune system to target and eradicate cancer cells. We do this using our engineered autologous cell therapy, which we believe is a transformational approach to the treatment of cancer. Our therapy involves genetically modifying a patient’s T cells outside the patient’s body, transforming the T cells to express chimeric antigen receptors (CARs), and then reinfusing the engineered T cells back into the patient. CARs can recognize native cancer antigens that are part of an intact protein presented on the cancer cell surface. UWELL BioPharma is a cellular therapy company based in New Taipei City, Taiwan. UWELL has a strong management team and a team of professional and experienced scientists who are developing cutting edge technology to help fight cancer. Uwell Has a strong collaboration and close interaction with excellent clinical teams and partners in Taiwan and China, as well as in Malaysia. UWELL has generated and advanced a broad portfolio of product candidates to target hematological tumors.